Ildong Holdings Co., Ltd. (000230.KS)
KRW 6600.0
(-5.44%)
KRW 6600.0
(-5.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 278.43 Billion KRW | -17.47% |
| 2022 | 337.39 Billion KRW | 11.53% |
| 2021 | 302.52 Billion KRW | 18.27% |
| 2020 | 255.79 Billion KRW | 80.66% |
| 2019 | 141.58 Billion KRW | 608.11% |
| 2018 | 19.99 Billion KRW | 0.01% |
| 2017 | 19.99 Billion KRW | -6.67% |
| 2016 | 21.42 Billion KRW | -89.94% |
| 2015 | 212.91 Billion KRW | 11.2% |
| 2014 | 191.48 Billion KRW | 6.86% |
| 2013 | 179.19 Billion KRW | 1.23% |
| 2012 | 177.01 Billion KRW | 10.12% |
| 2011 | 160.75 Billion KRW | 2.3% |
| 2010 | 157.14 Billion KRW | -15.79% |
| 2009 | 186.6 Billion KRW | -0.98% |
| 2008 | 188.44 Billion KRW | 10.8% |
| 2007 | 170.08 Billion KRW | 5.54% |
| 2006 | 161.16 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 167.66 Billion KRW | 190.5% |
| 2024 Q1 | 57.71 Billion KRW | -2.62% |
| 2024 Q3 | 166.46 Billion KRW | -65.98% |
| 2023 Q3 | -71.63 Billion KRW | -188.06% |
| 2023 Q2 | 81.34 Billion KRW | 6.36% |
| 2023 Q1 | 76.47 Billion KRW | -10.26% |
| 2023 Q4 | 59.26 Billion KRW | 182.74% |
| 2023 FY | 278.43 Billion KRW | -17.47% |
| 2022 FY | 337.39 Billion KRW | 11.53% |
| 2022 Q1 | 75.48 Billion KRW | -2.65% |
| 2022 Q2 | 89.85 Billion KRW | 19.04% |
| 2022 Q3 | 86.83 Billion KRW | -3.35% |
| 2022 Q4 | 85.22 Billion KRW | -1.86% |
| 2021 Q3 | 78.68 Billion KRW | 9.72% |
| 2021 Q4 | 77.53 Billion KRW | -1.46% |
| 2021 Q1 | 74.59 Billion KRW | 7.44% |
| 2021 Q2 | 71.71 Billion KRW | -3.86% |
| 2021 FY | 302.52 Billion KRW | 18.27% |
| 2020 Q4 | 69.42 Billion KRW | 1.94% |
| 2020 FY | 255.79 Billion KRW | 80.66% |
| 2020 Q1 | 58.37 Billion KRW | -14.01% |
| 2020 Q2 | 59.91 Billion KRW | 2.63% |
| 2020 Q3 | 68.09 Billion KRW | 13.67% |
| 2019 Q3 | 62.53 Billion KRW | 1018.94% |
| 2019 FY | 141.58 Billion KRW | 608.11% |
| 2019 Q2 | 5.58 Billion KRW | 0.2% |
| 2019 Q4 | 67.88 Billion KRW | 8.55% |
| 2019 Q1 | 5.57 Billion KRW | 5.82% |
| 2018 Q3 | 5.29 Billion KRW | 8.14% |
| 2018 Q1 | 4.52 Billion KRW | 0.99% |
| 2018 FY | 19.99 Billion KRW | 0.01% |
| 2018 Q4 | 5.27 Billion KRW | -0.49% |
| 2018 Q2 | 4.89 Billion KRW | 8.15% |
| 2017 Q3 | 4.93 Billion KRW | -13.47% |
| 2017 Q2 | 5.7 Billion KRW | 17.37% |
| 2017 Q1 | 4.86 Billion KRW | -7.2% |
| 2017 FY | 19.99 Billion KRW | -6.67% |
| 2017 Q4 | 4.48 Billion KRW | -9.18% |
| 2016 Q4 | 5.23 Billion KRW | -9.4% |
| 2016 FY | 21.42 Billion KRW | -89.94% |
| 2016 Q3 | 5.78 Billion KRW | 21.85% |
| 2016 Q2 | 4.74 Billion KRW | -91.12% |
| 2016 Q1 | 53.45 Billion KRW | -13.47% |
| 2015 FY | 212.91 Billion KRW | 11.2% |
| 2015 Q1 | 46.08 Billion KRW | -17.21% |
| 2015 Q2 | 51.9 Billion KRW | 12.62% |
| 2015 Q3 | 53.15 Billion KRW | 2.41% |
| 2015 Q4 | 61.77 Billion KRW | 16.22% |
| 2014 Q4 | 55.66 Billion KRW | 17.07% |
| 2014 Q3 | 47.54 Billion KRW | 1.52% |
| 2014 Q2 | 46.83 Billion KRW | 13.04% |
| 2014 Q1 | 41.43 Billion KRW | -16.92% |
| 2014 FY | 191.48 Billion KRW | 6.86% |
| 2013 FY | 179.19 Billion KRW | 1.23% |
| 2013 Q4 | 49.86 Billion KRW | 15.77% |
| 2013 Q1 | 40.47 Billion KRW | -11.97% |
| 2013 Q3 | 43.07 Billion KRW | -5.91% |
| 2013 Q2 | 45.77 Billion KRW | 13.11% |
| 2012 FY | 177.01 Billion KRW | 10.12% |
| 2012 Q4 | 45.97 Billion KRW | 1.52% |
| 2012 Q3 | 45.28 Billion KRW | 4.55% |
| 2012 Q2 | 43.31 Billion KRW | -0.43% |
| 2012 Q1 | 43.5 Billion KRW | 0.0% |
| 2011 FY | 160.75 Billion KRW | 2.3% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 43.66 Billion KRW | 16.12% |
| 2011 Q1 | 35.12 Billion KRW | 0.0% |
| 2011 Q2 | 37.6 Billion KRW | 7.04% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 157.14 Billion KRW | -15.79% |
| 2010 Q3 | 40.28 Billion KRW | 11.01% |
| 2010 Q2 | 36.29 Billion KRW | 0.0% |
| 2009 FY | 186.6 Billion KRW | -0.98% |
| 2009 Q2 | 36.77 Billion KRW | 0.0% |
| 2009 Q3 | 36.36 Billion KRW | -1.14% |
| 2009 Q4 | 35.79 Billion KRW | -1.56% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 Q4 | 35.88 Billion KRW | -2.21% |
| 2008 Q2 | 34.9 Billion KRW | 0.0% |
| 2008 Q3 | 36.69 Billion KRW | 5.14% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 FY | 188.44 Billion KRW | 10.8% |
| 2007 Q3 | 32.55 Billion KRW | 3.58% |
| 2007 FY | 170.08 Billion KRW | 5.54% |
| 2007 Q4 | 32.02 Billion KRW | -1.64% |
| 2007 Q2 | 31.43 Billion KRW | 0.0% |
| 2006 FY | 161.16 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -489.24% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 6.561% |
| HANDOK Inc. | 153.76 Billion KRW | -81.077% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -302.29% |
| Yuhan Corporation | 489.94 Billion KRW | 43.169% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 9.291% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -566.29% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 54.427% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -286.81% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -59.886% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -595.174% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -197.632% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -142.701% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -489.24% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -555.586% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -271.009% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -374.793% |
| JW Holdings Corporation | 301.25 Billion KRW | 7.574% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -6.7% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 31.865% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -16.545% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -118.094% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -307.605% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -323.472% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -59.175% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -489.24% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -11.768% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 50.317% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -16.545% |
| Yuhan Corporation | 489.94 Billion KRW | 43.169% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -43.775% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -300.813% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -396.928% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -16.545% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -120.296% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -135.538% |
| CKD Bio Corp. | 25.19 Billion KRW | -1005.103% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -25.424% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -68.635% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -319.226% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -118.094% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 20.608% |
| Boryung Corporation | 285.16 Billion KRW | 2.358% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -218.063% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -59.886% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1274.222% |